Frances Arnold

October 17, 2026

Alphabet's Gemini AI appears in Geely's overseas car exports. Google has integrated its Gemini generative AI model into Geely's overseas car models, allowing the automaker to use AI features in exported vehicles. This expands Alphabet's AI reach beyond its own services and may create new licensing revenue. Analysts also cite a forecast that Alphabet could become larger than Apple by 2027, indicating confidence in its growth. The stock is near its $340 support level, with a neutral RSI and a trailing P/E of 17.4.

October 1, 2026

Generate Biomedicines Doses First Patient in GB-5267 CAR T Trial. Generate Biomedicines announced that the first patient has received the investigational GB-5267 therapy in a first‑in‑human trial at Roswell Park. This marks the first dose of the IL‑18 armored CAR‑T cell product and represents a key step toward clinical development. The announcement signals progress in the company’s pipeline and may influence investor perception of its therapeutic potential.

October 17, 2026

Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.